These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38550142)

  • 1. Retracted: Discovery of New Therapeutic Targets for Osteosarcoma Treatment Based on Immune-Related lncRNAs in the Tumor Microenvironment.
    International BR
    Biomed Res Int; 2024; 2024():9786305. PubMed ID: 38550142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of New Therapeutic Targets for Osteosarcoma Treatment Based on Immune-Related lncRNAs in the Tumor Microenvironment.
    Fu R; Hong X
    Biomed Res Int; 2022; 2022():3113857. PubMed ID: 35528175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retracted: Identification of Prognostic LncRNAs Subtypes Predicts Prognosis and Immune Microenvironment for Glioma.
    And Alternative Medicine EC
    Evid Based Complement Alternat Med; 2023; 2023():9761231. PubMed ID: 37388089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. m6A-Related lncRNAs Predict Overall Survival of Patients and Regulate the Tumor Immune Microenvironment in Osteosarcoma.
    Bi Y; Meng D; Wan M; Xu N; Xu Y; Yuan K; Liu P; Fang H; Hu H; Lan S
    Comput Intell Neurosci; 2022; 2022():9315283. PubMed ID: 35978902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma.
    Wu Z; Zhang X; Chen D; Li Z; Wu X; Wang J; Deng Y
    Front Immunol; 2021; 12():806189. PubMed ID: 35095893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N6-Methyladenosine-Related lncRNAs Are Potential Prognostic Biomarkers and Correlated With Tumor Immune Microenvironment in Osteosarcoma.
    Zheng D; Yu L; Wei Z; Xia K; Guo W
    Front Genet; 2021; 12():805607. PubMed ID: 35186011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retracted: Identification of Therapeutic Targets and Prognostic Biomarkers among Genes from the Mediator Complex Family in the Hepatocellular Carcinoma Tumour-Immune Microenvironment.
    Methods In Medicine CAM
    Comput Math Methods Med; 2023; 2023():9760920. PubMed ID: 38094413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value and immune landscapes of m1A/m5C/m6A-associated lncRNA signature in osteosarcoma.
    Wu ZY; Shi ZY
    Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5868-5883. PubMed ID: 36066162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of an Immune-Related lncRNA Signature That Predicts Prognosis and Immune Microenvironment in Osteosarcoma Patients.
    He Y; Zhou H; Xu H; You H; Cheng H
    Front Oncol; 2022; 12():769202. PubMed ID: 35494024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retracted: Verification of Ferroptosis Subcluster-Associated Genes Related to Osteosarcoma and Exploration of Immune Targeted Therapy.
    Longevity OMAC
    Oxid Med Cell Longev; 2023; 2023():9768692. PubMed ID: 38189014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Retracted] STK39, overexpressed in osteosarcoma, regulates osteosarcoma cell invasion and proliferation.
    Huang T; Zhou Y; Cao Y; Tao J; Zhou ZH; Hang DH
    Oncol Lett; 2024 Aug; 28(2):377. PubMed ID: 38939622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-Related LncRNAs Affect the Prognosis of Osteosarcoma, Which Are Related to the Tumor Immune Microenvironment.
    Huang Q; Lin Y; Chen C; Lou J; Ren T; Huang Y; Zhang H; Yu Y; Guo Y; Wang W; Wang B; Niu J; Xu J; Guo L; Guo W
    Front Cell Dev Biol; 2021; 9():731311. PubMed ID: 34692688
    [No Abstract]   [Full Text] [Related]  

  • 13. Retracted: Identification of Clinical Prognostic Regulators and Analysis of Ferroptosis-Related Signatures in the Tumor Immune Microenvironment in Lung Squamous Cell Carcinoma.
    Markers D
    Dis Markers; 2023; 2023():9893453. PubMed ID: 37387739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retracted: mir-204-5p Acts as a Tumor Suppressor by Targeting DNM2 in Osteosarcoma Cells.
    Engineering JOH
    J Healthc Eng; 2023; 2023():9827523. PubMed ID: 36718171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retracted: Understanding the Critical Role of Glycolysis-Related lncRNAs in Lung Adenocarcinoma Based on Three Molecular Subtypes.
    International BR
    Biomed Res Int; 2024; 2024():9891572. PubMed ID: 38550168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retracted: Comprehensive Analysis of Subtypes and Identification of Key lncRNAs Based on Glutamine Metabolism-Related Long Noncoding RNAs.
    Methods In Medicine CAM
    Comput Math Methods Med; 2023; 2023():9849047. PubMed ID: 38124932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retracted: GNAI2 Is a Risk Factor for Gastric Cancer: Study of Tumor Microenvironment (TME) and Establishment of Immune Risk Score (IRS).
    Longevity OMAC
    Oxid Med Cell Longev; 2023; 2023():9873973. PubMed ID: 37810556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retracted: A Novel Necroptosis-Related lncRNA Signature for Osteosarcoma.
    Methods In Medicine CAM
    Comput Math Methods Med; 2023; 2023():9812519. PubMed ID: 38077915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retracted: Clinical Application of Artificial Intelligence: Auto-Discerning the Effectiveness of Lidocaine Concentration Levels in Osteosarcoma Femoral Tumor Segment Resection.
    Healthcare Engineering JO
    J Healthc Eng; 2023; 2023():9816857. PubMed ID: 37860374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retracted: Effect of Paclitaxel Combined with Doxorubicin Hydrochloride Liposome Injection in the Treatment of Osteosarcoma and MRI Changes before and after Treatment.
    And Alternative Medicine EC
    Evid Based Complement Alternat Med; 2023; 2023():9816837. PubMed ID: 37501833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.